


CLAIMS

1. A compound of formula (I):



Formula (I)

5

wherein


*1 denotes a chiral centre

 $n = 0, 1$ or 2 ;A is selected from H, $-(C=O)R_4$, $-SO_2R_6$, and $-(CH_2)-R_{13}$;

10

Y is either a bond, or $-[CHR_5]-$; R_1 is H or alkyl^b; R_2^A is selected from H, alkyl, $-(CH_2)_{0-3}$ aryl, $-(CH_2)_{0-3}$ heteroaryl, $-(CH_2)_{0-3}$ cycloalkyl,

15

 $-(CH_2)_{0-3}$ -[benzothiophene], $-(CH_2)_{0-3}$ -[indole], and

when Y is a bond, R_1 and R_2^A , together with nitrogen atom to which R_1 is attached and the carbon atom to which R_2^A is attached, may be linked by alkylene to form a 4-, 5-, or 6-membered saturated heterocycle, optionally wherein the 4-, 5-, or 6-membered saturated heterocycle may be substituted with aryl, or wherein two adjacent carbon atoms on the 4-, 5-, or 6-membered saturated heterocycle may be linked to form a 6-membered aromatic ring, or wherein two adjacent carbon atoms on the 4-, 5-, or 6-membered saturated heterocycle may be linked to form a 3-, 4-, or 5-membered saturated hydrocarbon ring which may be optionally mono- or di-substituted by alkyl^b;

20

25

when Y is $-[CHR_5]-$, R_5 is H; or,

when Y is $-[CHR_5]-$, together with the carbon atoms to which each of R_5 and R_2^A are attached, R_5 and R_2^A may be linked by alkylene to form a 4-, 5-, 6-membered saturated ring;

or,

when Y is $-[CHR_5]-$, together with the nitrogen atom to which R_1 is attached, the carbon atom to which R_5 is attached, and the carbon atom to which R_2^A and R_2^B are both attached,

30

R5 and R1 may be linked by alkylene to form a saturated 4-, 5-, or 6-membered heterocycle, optionally wherein one atom on the saturated 4-, 5-, or 6- membered heterocycle may be linked by alkylene to join with R2^A;

5 R2^B is H or alkyl^b; or,

R2^A and R2^B, together with the carbon to which R2^A and R2^B are both attached, may be linked by alkylene or heteroalkylene to form a 3-, 4-, 5-, or 6- membered saturated ring, optionally wherein the 3-, 4-, 5-, or 6- membered saturated ring contains one or two ring members that are selected from N and O;

10

R3 is:

(i) a fused 6,5- or 6,6- bicyclic ring, containing one heteroatom selected from S and N, wherein at least one of the rings is aromatic and, optionally the bicyclic ring contains one additional heteroatom independently selected from N, O and S;


15

optionally wherein the fused 6,5- or 6,6- bicyclic ring may be substituted with 1, 2, or 3 substituents selected from alkyl^b, alkoxy, OH, NH₂, halo, CN, and CF₃; wherein the fused 6,5- bicyclic ring may be attached via the 6- or 5- membered ring; or

(ii) phenyl, pyridyl, or thiophenyl, which may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl^b, alkoxy, OH, NH₂, halo, CN, CF₃, -C(=NH)NH₂, and heteroaryl^b;

20


wherein when n=1, and R3 is phenyl substituted with at least one -(CH₂NH₂), R2^A is alkyl and R2^B is H; or



25

R4 is one of:

(i) a group of formula (II),




Formula (II)

wherein -[L]- is a bond, -[(CH₂)₁₋₄]-, -[(CH₂)-O-(CH₂)]-, or -[O-(CH₂)]-; and P is alkoxy, OH or NR₁₁R₁₂;

wherein *2 denotes a chiral centre, and

5 wherein when -[L]- is a bond, B is a C₁₋₄ linear or branched chain hydrocarbon, and

wherein when -[L]- is -[(CH₂)₁₋₄]-, -[(CH₂)-O-(CH₂)]-, or -[O-(CH₂)]-, B is OH, aryl,



(ii) -(CH₂)_m-[fused 6,5- or 6,6- heteroaromatic bicyclic ring], wherein at least one ring atom is a heteroatom selected from O, N or S, and optionally, 1, 2 or 3 additional ring atoms may be selected from N or NH; wherein the fused 6,5- or

10 6,6- heteroaromatic bicyclic ring may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl^b; wherein the 6,5- heteroaromatic bicyclic ring may be attached to -(CH₂)_m- via the 6- or 5- membered ring; or,

(iii) methyl, -C(CH₃)₂(OH), -C(CH₃)₂(NHMe), -(CH₂)_m-(aryl), -(CH₂)_m-(cycloalkyl),
15 -(CH₂)_m-(heteroaryl), -(CH₂)_m-(heterocyclyl), -(CH₂)-(alkyl), -(CH(halo)₂),
-(CH₂)_m-(NR₈R₉), -(CH₂)_m-(NR₁₀R₇), -(CH₂)_m-O-(CH₂)_k-(aryl), -(CH₂)_m-(SO₂)-(CH₂)_k-(aryl),
-(CH₂)_m-(alkoxy), -(CH₂)_m-O-(CH₂)_k-(heteroaryl), or -(CH₂)_m-[pyridone, which may be
optionally substituted by alkyl^b, or CF₃];


20

wherein k = 0, 1, 2, or 3;


wherein m = 0, 1, 2 or 3;

wherein:

25 when Y is -[CHR₅]- and R₅ is H, R^{2A} is CH₂-aryl or H; and



275



wherein:

5

R6 is alkyl or $-(CH_2)_{0-3}-(aryl)$;

R7 is independently selected from H, $-SO_2CH_3$, methyl, ethyl, propyl, isopropyl, and cycloalkyl;

10

R8 and R9 are independently selected from H, $-SO_2CH_3$, alkyl^b, heteroaryl^b, and cycloalkyl; or R8 and R9 together with the nitrogen atom to which they are attached form a carbon-containing 4-, 5-, 6- or 7-membered heterocyclic ring, optionally containing an additional heteroatom selected from N, NR10, S, and O, which may be saturated or unsaturated with 1 or 2 double bonds and which may be optionally mono- or di-substituted with substituents independently selected from oxo, alkyl^b, alkoxy, OH, halo, $-SO_2CH_3$, and CF_3 ; or R8 and R9 together with the nitrogen atom to which they are attached form a carbon-containing 5- or 6- membered heterocyclic ring, which is fused to an aryl^b or a heteroaryl^b;

15

20

R10 is independently selected from H, $-SO_2R_6$, alkyl^b, $-(CH_2)_{0-3}aryl^b$, $-(CH_2)_{0-3}heteroaryl^b$, cycloalkyl, $-(C=O)-(aryl)$, and $-(CH_2)_{0-3}heterocyclyl^b$; or R10 is a carbon-containing 4-, 5-, 6- or 7-membered heterocyclic ring, optionally containing an additional heteroatom selected from N, NR7, S, SO, SO_2 , and O, which may be saturated or unsaturated with 1 or 2 double bonds and which may be optionally mono- or di-substituted with substituents independently selected from oxo, alkyl^b, alkoxy, OH, halo, $-SO_2CH_3$, and CF_3 ;

25

R11 and R12 are independently selected from H, alkyl^b, -SO₂R6, cycloalkyl, -(C=O)O-(alkyl^b), -(C=O)-phenyl, -CH₂-phenyl, and CH₂-COOH; or R11 and R12 together with the nitrogen atom to which they are attached form a carbon-containing 4-, 5-, 6- or 7-membered heterocyclic ring optionally containing an additional heteroatom selected from N, O, and NR10, wherein the heterocyclic ring may be optionally mono- or di-substituted with substituents independently selected from alkyl^b, OH, halo and CF₃;

R13 is selected from heteroaryl, cycloalkyl, heterocyclyl and aryl^b;

wherein:

alkoxy is a linear O-linked hydrocarbon of between 1 and 6 carbon atoms (C₁-C₆) or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C₃-C₆); alkoxy may optionally be substituted with 1 or 2 substituents independently selected from OH, CN, CF₃, -N(R7)₂ and fluoro;

alkyl is a linear saturated hydrocarbon having up to 6 carbon atoms (C₁-C₆) or a branched saturated hydrocarbon of between 3 and 6 carbon atoms (C₃-C₆); alkyl may optionally be substituted with 1 or 2 substituents independently selected from (C₁-C₆)alkoxy, OH, -NR8R9, -NHCOCH₃, -CO(heterocyclyl^b), -COOR8, -CONR8R9, CN, CF₃, halo, oxo and heterocyclyl^b;

alkyl^b is a linear saturated hydrocarbon having up to 6 carbon atoms (C₁-C₆) or a branched saturated hydrocarbon of between 3 and 6 carbon atoms (C₃-C₆); alkyl may optionally be substituted with 1 or 2 substituents independently selected from (C₁-C₆)alkoxy, OH, -N(R7)₂, -NHCOCH₃, CF₃, halo, oxo and cyclopropane;

alkylene is a bivalent linear saturated hydrocarbon having 1 to 5 carbon atoms (C₁-C₅); alkylene may optionally be substituted with 1 or 2 substituents independently selected from alkyl, (C₁-C₆)alkoxy, OH, CN, CF₃ and halo;

aryl is phenyl, biphenyl or naphthyl; aryl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, -SO₂CH₃, halo, -SO₂NR8R9, CN, -(CH₂)₀₋₃-O-heteroaryl^b, aryl^b, -O-aryl^b, -(CH₂)₀₋₃-heterocyclyl^b, -(CH₂)₁₋₃-aryl^b, -(CH₂)₀₋₃-heteroaryl^b, -COOR8, -CONR8R9, -(CH₂)₀₋₃-NR8R9, OCF₃ and CF₃; or

two adjacent carbon ring atoms on the aryl may be optionally linked by a heteroalkylene to form a non-aromatic ring containing 5, 6, or 7 ring members which may be optionally substituted with OH; or optionally wherein two adjacent ring atoms on aryl are linked to form a 5- or 6- membered aromatic ring containing 1 or 2 heteroatoms that are selected from N, NR10, S, and O;

aryl^b is phenyl, biphenyl or naphthyl, which may be optionally substituted with 1, 2 or 3 substituents independently selected from methyl, ethyl, propyl, isopropyl, alkoxy, OH, -SO₂CH₃, N(R7)₂, halo, CN, and CF₃; or two adjacent carbon ring atoms on the aryl may be optionally linked by a heteroalkylene to form a non-aromatic ring containing 5, 6, or 7 ring members;

cycloalkyl is monocyclic saturated hydrocarbon ring of between 3 and 6 carbon atoms (C₃-C₆); cycloalkyl may optionally be substituted with 1 or 2 substituents independently selected from methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, propoxy, isopropoxy, OH, CN, CF₃ and halo; optionally wherein two adjacent ring atoms on cycloalkyl are linked to form a 5- or 6-membered saturated hydrocarbon ring;

halo is F, Cl, Br, or I;

heteroalkylene is a bivalent linear saturated hydrocarbon having 2 to 5 carbon atoms (C₂-C₅), wherein 1 or 2 of the 2 to 5 carbon atoms are replaced with NR10, S, or O; heteroalkylene may optionally be substituted with 1 or 2 substituents independently selected from alkyl, (C₁-C₆)alkoxy, OH, CN, CF₃ and halo;

heteroaryl is a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members that are selected from N, NR10, S, and O; heteroaryl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, heteroaryl^b, phenyl, cycloalkyl, OH, OCF₃, halo, heterocycl^b, CN, and CF₃;

heteroaryl^b is a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members that are selected from N, NR10, S, and O; heteroaryl^b may be optionally substituted with 1, 2 or 3 substituents independently selected from methyl, ethyl, propyl,

isopropyl, alkoxy, OH, OCF₃, COOCH₃, COOCH₂CH₃, COO-(CH₂)₂-CH₃, COO-(iPr), halo, CN, and CF₃;

5 heterocyclyl is a 4-, 5-, 6-, or 7- membered carbon-containing non-aromatic ring containing one, two, three, or four ring members that are selected from N, NR₁₀, S, SO, SO₂ and O; heterocyclyl may be optionally substituted with 1, 2, 3, or 4 substituents independently selected from alkyl, alkoxy, aryl^b, OH, OCF₃, halo, oxo, CN, NR_{8R9}, -O(aryl^b), -O(heteroaryl^b) and CF₃; or optionally wherein two ring atoms on heterocyclyl are linked with an alkylene to form a non-aromatic ring containing 5, 6, or 7 ring members; or optionally wherein two ring
10 atoms on heterocyclyl are linked with an heteroalkylene to form a non-aromatic ring containing 5, 6, or 7 ring members; or optionally wherein two adjacent ring atoms on heterocyclyl are linked to form a 5- or 6- membered aromatic ring which may optionally contain 1 or 2 heteroatoms that are selected from N, NR₁₀, S, and O;

15 heterocyclyl^b is a 4-, 5-, 6-, or 7- membered carbon-containing non-aromatic ring containing one, two or three ring members that are selected from N, NR₇, S, SO, SO₂ and O; heterocyclyl^b may be optionally substituted with 1, 2, 3, or 4 substituents independently selected from methyl, ethyl, propyl, isopropyl, alkoxy, OH, OCF₃, halo, oxo, CN, and CF₃;

20 and tautomers, isomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), deuterated isotopes, and pharmaceutically acceptable salts and/or solvates thereof.


2. A compound of formula (I) according to claim 1, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a
25 deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof, wherein n = 1.

3. A compound of formula (I) according to any preceding claim, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or
30 solvate thereof, wherein A is -(C=O)R₄.

4. A compound of formula (I) according to any preceding claim, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or


solvate thereof,

wherein R4 is a group of formula (II),



Formula (II)

- 5 wherein -[L]- is -[(CH₂)₁₋₄]-, -[(CH₂)-O-(CH₂)]-, or -[O-(CH₂)]-;
 P is alkoxy, OH or NR¹¹R¹²;



and B is OH, aryl, heteroaryl, heterocyclyl, cycloalkyl or

5. A compound of formula (I) according to any preceding claim, or a tautomer, isomer,
 stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic
 10 mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or
 solvate thereof,
 wherein P is NR¹¹R¹².
6. A compound of formula (I) according to any preceding claim, or a tautomer, isomer,
 stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic
 15 mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or
 solvate thereof,
 wherein P is NHR¹².
7. A compound of formula (I) according to any preceding claim, or a tautomer, isomer,
 stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic
 20 mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or
 solvate thereof,
 wherein P is selected from NH₂, NH(alkyl) and NH(cyclohexyl).
8. A compound of formula (I) according to any preceding claim, or a tautomer, isomer,
 stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic
 25 mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or
 solvate thereof,
 wherein P is NH₂.
9. A compound of formula (I) according to any one of claims 1 to 7, or a tautomer, isomer,
 stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic
 30 mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or

solvate thereof,

wherein P is NH(iPr).

10. A compound of formula (I) according to any one of claims 1 to 7, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof, wherein P is NH(cyclohexyl).
11. A compound of formula (I) according to any one of claims 1 to 5, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof, wherein P is N-linked pyrrolidiny.
12. A compound of formula (I) according to any preceding claim, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof, wherein -[L]- is $-\text{[(CH}_2\text{)}_{1-4}\text{]}-$.
13. A compound of formula (I) according to any preceding claim, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof, wherein -[L]- is $-\text{[(CH}_2\text{)}_2\text{]}-$.
14. A compound of formula (I) according to any one of claims 1 to 12, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof, wherein -[L]- is $-\text{[(CH}_2\text{)}_4\text{]}-$.
15. A compound of formula (I) according to any preceding claim, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof, wherein B is aryl.
16. A compound of formula (I) according to any preceding claim, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic


mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,
wherein B is phenyl.

17. A compound of formula (I) according to any one of claims 1 to 14, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,
wherein B is heterocyclyl.

18. A compound of formula (I) according to any one of claims 1 to 14 and 17, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,
wherein B is piperidinyl.

19. A compound of formula (I) according to any one of claims 1 to 3, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,
wherein R4 is $-(CH_2)_m-(\text{heterocyclyl})$.

20. A compound of formula (I) according to any one of claims 1 and 19, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,




wherein R4 is

21. A compound of formula (I) according to any one of claims 1 to 3, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,
wherein R4 is $-(CH_2)_m-(NR_8R_9)$.

22. A compound of formula (I) according to claim 88, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a

deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,



wherein $-(NR_8R_9)$ is

23. A compound of formula (I) according to any of claims 1 to 2, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,


wherein A is $-SO_2R_6$.

24. A compound of formula (I) according any preceding claim, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,

wherein R_1 is H.

25. A compound of formula (I) according to any preceding claim, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,

wherein R_2^A is selected from H, alkyl, $-(CH_2)_{0-3}$ aryl, $-(CH_2)_{0-3}$ heteroaryl, $-(CH_2)_{0-3}$ cycloalkyl,



26. A compound of formula (I) according to any preceding claim, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,

wherein R_2^A is alkyl.

27. A compound of formula (I) according to any preceding claim, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,


wherein R_2^A is methyl.

28. A compound of formula (I) according to any one of claims 1 to 25, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic


mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,

wherein $R2^A$ is $-(CH_2)_{0-3}$ aryl.

29. A compound of formula (I) according to any one of claims 1 to 25 and 28, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,




wherein $R2^A$ is selected from , $-(CH_2)$ -[naphthyl], $-(CH_2)$ -[mono-, or di- chlorophenyl], $-(CH_2)$ -[mono-, or di- fluorophenyl], $-(CH_2)$ -phenyl, -

$(CH_2)_2$ -phenyl, $-(CH_2)$ - and $-(CH_2)$ -biphenyl.

The structure shows a benzene ring with a methoxy group (OMe) at the 4 position. It is enclosed in brackets with a wavy line on the left and a bond on the right, indicating it is a substituent.

30. A compound of formula (I) according to any one of claims 1 to 25 and 28 to 29, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,



wherein $R2^A$ is  .

31. A compound of formula (I) according to any one of claims 1 to 23, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,
- wherein $R1$ and $R2^A$, together with nitrogen atom to which $R1$ is attached and the carbon atom to which $R2^A$ is attached, are linked by alkylene to form a 4-, 5-, or 6- membered saturated heterocycle.

32. A compound of formula (I) according to any one of claims 1 to 23 and 32, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt

and/or solvate thereof,

wherein R1 and R2^A, together with nitrogen atom to which R1 is attached and the carbon atom to which R2^A is attached, are linked by alkylene to form a 4- membered saturated heterocycle.

- 5 33. A compound of formula (I) according to any preceding claim, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof, wherein Y is a bond.
- 10 34. A compound of formula (I) according to any one of claims 1 to 23 and 33, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof, wherein R2^A and R2^B, together with the carbon to which R2^A and R2^B are both attached, are
- 15 linked by alkylene or heteroalkylene to form a 3-, 4-, 5-, or 6- membered saturated ring.
35. A compound of formula (I) according to any preceding claim, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,
- 20 wherein R3 is a fused 6,5- or 6,6- bicyclic ring, containing one heteroatom selected from S and N, wherein at least one of the rings is aromatic and, optionally the bicyclic ring contains one additional heteroatom independently selected from N, O and S; optionally wherein the fused 6,5- or 6,6- bicyclic ring may be substituted with 1, 2, or 3 substituents selected from alkyl^b, alkoxy, OH, NH₂, halo, CN, and CF₃;
- 25 wherein the fused 6,5- bicyclic ring may be attached via the 6- or 5- membered ring.
36. A compound of formula (I) according to any preceding claim, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,
- 30 wherein R3 is a fused 6,5- or 6,6- bicyclic ring, containing a N atom and, optionally the bicyclic ring contains one additional heteroatom independently selected from N, and O.
37. A compound of formula (I) according to any one of claims 1 to 35, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or

solvate thereof,

wherein R3 is a fused 6,5- or 6,6- bicyclic ring, containing one S atom, wherein at least one of the rings is aromatic;

wherein the fused 6,5- or 6,6- bicyclic ring is substituted with 1, 2, or 3 substituents selected from alkyl^b, alkoxy, OH, NH₂, halo, CN, and CF₃;

wherein the fused 6,5- bicyclic ring may be attached via the 6- or 5- membered ring.

38. A compound of formula (I) according to any one of claims 1 to 36, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,

wherein R3 is a fused 6,5- or 6,6- bicyclic ring, containing two N atoms, wherein at least one of the rings is aromatic, optionally wherein the fused 6,5- or 6,6- bicyclic ring may be substituted with 1, 2, or 3 substituents selected from alkyl^b, alkoxy, OH, NH₂, halo, CN, and CF₃;

wherein the fused 6,5- bicyclic ring may be attached via the 6- or 5- membered ring.

39. A compound of formula (I) according to any one of claims 1 to 36, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,

wherein R3 is a fused 6,5- or 6,6- bicyclic ring, containing one N atom, wherein at least one of the rings is aromatic, optionally wherein the fused 6,5- or 6,6- bicyclic ring may be substituted with 1, 2, or 3 substituents selected from alkyl^b, alkoxy, OH, NH₂, halo, CN, and CF₃;

wherein the fused 6,5- bicyclic ring may be attached via the 6- or 5- membered ring.


40. A compound of formula (I) according to any one of claims 1 to 36, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,

wherein R3 is a fused 6,5- or 6,6- bicyclic ring, containing one N atom and one O atom,

wherein at least one of the rings is aromatic, optionally wherein the fused 6,5- or 6,6- bicyclic ring may be substituted with 1, 2, or 3 substituents selected from alkyl^b, alkoxy, OH, NH₂, halo, CN, and CF₃;


wherein the fused 6,5- bicyclic ring may be attached via the 6- or 5- membered ring.

41. A compound of formula (I) according to any one of claims 1 to 35, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,
- 5 wherein R3 is a fused 6,5- or 6,6- bicyclic ring, containing one N atom and one S atom, wherein at least one of the rings is aromatic, optionally wherein the fused 6,5- or 6,6- bicyclic ring may be substituted with 1, 2, or 3 substituents selected from alkyl^b, alkoxy, OH, NH₂, halo, CN, and CF₃;
- wherein the fused 6,5- bicyclic ring may be attached via the 6- or 5- membered ring.
- 10 42. A compound of formula (I) according to any one of claims 1 to 34, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,
- wherein R3 is phenyl, pyridyl, or thiophenyl, which may be optionally substituted with 1, 2 or
- 15 3 substituents independently selected from alkyl^b, alkoxy, OH, NH₂, halo, CN, CF₃, -C(=NH)NH₂, and heteroaryl^b.
43. A compound of formula (I) according to any one of claims 1 to 34, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or
- 20 solvate thereof,




wherein R3 is


44. A compound of formula (I) according to any one of claims 1 to 34, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or
- 25 solvate thereof,



wherein R3 is selected from:



45. A compound of formula (I) according to claim 44, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,



46. A compound of formula (I) according to any preceding claim, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,
- 5 wherein chiral centre *1 is in the (S)- configuration.
47. A compound of formula (I) according to any preceding claim, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof,
- 10 wherein chiral centre *2 is in the (R)- configuration.
48. A compound selected from any one of Tables 1 to 23, and pharmaceutically acceptable salts and/or solvates thereof.
- 15 49. A pharmaceutical composition comprising: a compound, or a pharmaceutically acceptable salt and/or solvate thereof, according to any of claims 1 to 48, and at least one pharmaceutically acceptable excipient.
50. A compound, or a pharmaceutically acceptable salt and/or solvate thereof, as claimed in any of claims 1 to 48, or the pharmaceutical composition according to claim 49, for use in
- 20 medicine.
51. The use of a compound, or a pharmaceutically acceptable salt and/or solvate thereof, as claimed in any of claims 1 to 48, or the pharmaceutical composition as claimed in claim 49, in the manufacture of a medicament for the treatment or prevention of a disease or condition in which Factor XIIIa activity is implicated.

52. A method of treatment of a disease or condition in which Factor XIIa activity is implicated comprising administration to a subject in need thereof a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt and/or solvate thereof, as claimed in any of claims 1 to 48, or the pharmaceutical composition as claimed in claim 49.
- 5 53. A compound, or a pharmaceutically acceptable salt and/or solvate thereof, as claimed in any of claims 1 to 48, or a pharmaceutical composition as claimed in claim 49, for use in a method of treatment of a disease or condition in which Factor XIIa activity is implicated.
54. The use of claim 51, the method of claim 52, or a compound, a pharmaceutically acceptable salt and/or solvate thereof, or a pharmaceutical composition for use as claimed 53, wherein,
10 the disease or condition in which Factor XIIa activity is implicated is a bradykinin-mediated angioedema.
55. The use of claim 54, the method of claim 54, or a compound, a pharmaceutically acceptable salt and/or solvate thereof, or a pharmaceutical composition for use as claimed in claim 54, wherein the bradykinin-mediated angioedema is hereditary angioedema.
- 15 56. The use of claim 54, the method of claim 54, or a compound, a pharmaceutically acceptable salt and/or solvate thereof, or a pharmaceutical composition for use as claimed in claim 54, wherein the bradykinin-mediated angioedema is non hereditary.
57. The use of claim 51, the method of claim 52, or a compound, a pharmaceutically acceptable salt and/or solvate thereof, or a pharmaceutical composition for use as claimed in claim 53,
20 wherein the disease or condition in which Factor XIIa activity is implicated is selected from vascular hyperpermeability; stroke including ischemic stroke and haemorrhagic accidents; retinal edema; diabetic retinopathy; DME; retinal vein occlusion; and AMD.
58. The use of claim 51, the method of claim 52, or a compound, a pharmaceutically acceptable salt and/or solvate thereof, or a pharmaceutical composition for use as claimed in claim 53,
25 wherein, the disease or condition in which Factor XIIa activity is implicated is a thrombotic disorder.
59. The use of claim 58, the method of claim 58, or a compound, a pharmaceutically acceptable salt and/or solvate thereof, or a pharmaceutical composition for use as claimed in claim 58,
30 wherein the thrombotic disorder is thrombosis; thromboembolism caused by increased propensity of medical devices that come into contact with blood to clot blood; prothrombotic conditions such as disseminated intravascular coagulation (DIC), venous thromboembolism (VTE), cancer associated thrombosis, complications caused by mechanical

and bioprosthetic heart valves, complications caused by catheters, complications caused by ECMO, complications caused by LVAD, complications caused by dialysis, complications caused by CPB, sickle cell disease, joint arthroplasty, thrombosis induced to tPA, Paget Schroetter syndrome and Budd-Chari syndrome; and atherosclerosis.

- 5 60. The use of claim 51, the method of claim 52, or a compound, a pharmaceutically acceptable salt and/or solvate thereof, or a pharmaceutical composition for use as claimed in claim 53, wherein, the disease or condition in which Factor XIIa activity is implicated is selected from neuroinflammation; neuroinflammatory/neurodegenerative disorders such as MS (multiple sclerosis); other neurodegenerative diseases such as Alzheimer's disease, epilepsy and
- 10 migraine; sepsis; bacterial sepsis; inflammation; vascular hyperpermeability; and anaphylaxis.
61. The use of any of claims 51 or 54 to 60, the method of any of claims 52 or 54 to 60, or a compound, a pharmaceutically acceptable salt and/or solvate thereof, or a pharmaceutical composition for use as defined in any of claims 53 or 54 to 60, wherein the compound
- 15 targets FXIIa.